Fri, Jan 30, 2015, 5:39 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

davide132 6 posts  |  Last Activity: Dec 26, 2014 11:04 AM Member since: Apr 13, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • davide132 by davide132 Dec 26, 2014 11:04 AM Flag

    Some nice call buys today Jan 7.5 and Jan 10 and Feb 10. Good volume today on a quiet day. We should head higher before ACLF data out. Good results can propel CNAT to 300M market cap.

  • Reply to

    presentation

    by cnlg1000 Dec 2, 2014 12:15 PM
    davide132 davide132 Dec 2, 2014 2:15 PM Flag

    I did find a Nov 19th presentation which is the week after the earnings release and stated that ACLF results are due 4Q 2014. From the earnings, I assumed we will be getting the results in January but we might get them this month.

  • Reply to

    presentation

    by cnlg1000 Dec 2, 2014 12:15 PM
    davide132 davide132 Dec 2, 2014 12:55 PM Flag

    I went on their website and can't find the presentation.

  • Dr. David Bernstein, chief of hepatology at North Shore University Hospital in Manhasset, N.Y., called the Conatus drug exciting and the initial trial a sensible approach.

    "There's limited downside because there's nothing else that can be done anyway," said Bernstein, who expects to be involved in future emricasan trials. "If you can reverse cirrhosis, you really will change the impact of liver disease worldwide."

    Drugs that succeed in reversing cirrhosis "can be as big a class as the class of statins," said Conatus's Mento, referring to cholesterol drugs, such as Pfizer's Lipitor, which alone at its peak had annual sales of about $13 billion

  • With positive phase 2 results, we should expect CNAT to reach 300M market cap and potentially as high as 500M with traders pushing it to those levels. It reminds of KERX when it jumped to about 500M market cap after their P2 results. Sweet spot in biotechs are phase 2 so if we get positive results we should move up. ACLF market is estimated at $2-3B per year and CNAT only company with ongoing trials.

  • davide132 by davide132 Nov 12, 2014 11:36 AM Flag

    Last patient was enrolled on or near Oct 1st and took the drug for 28 days. Let's assume it takes 2 weeks for them to get results bring us to a timeline between now and November 19th. Stock is being manipulated and seems like it does not want to go up. Very frustrating to watch but let's see if we can get the ACLF results soon to change direction.

KERX
12.16-0.500(-3.95%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.